secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102985
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q2 2025 rev $110.6M, Attruby sales $71.5M, net loss $181.9M
---------------------------------------------------------------------

- Total revenue $110.6M vs $2.2M prior year; Attruby net product revenue $71.5M.
- Net loss attributable to common stockholders $181.9M ($0.95 EPS) vs $73.5M ($0.39 EPS) prior year.
- As of Aug 1, 2025, 3,751 unique patient prescriptions for Attruby by 1,074 prescribers; launch accelerating.
- Pipeline: FORTIFY (LGMD2I/R9) and CALIBRATE (ADH1) topline results expected fall 2025; PROPEL 3 (achondroplasia) early 2026.
- Cash, cash equivalents and marketable securities $756.9M; raised $300M via royalty sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/0000950170-25-102985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/bbio-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer